Cogent Biosciences (COGT) Competitors

Cogent Biosciences (NASDAQ:COGT) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, community ranking, institutional ownership, profitability, valuation, analyst recommendations and media sentiment.

Is COGT or ENLV more profitable?

Enlivex Therapeutics' return on equity of -71.76% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-100.92%	-57.67%
Enlivex Therapeutics	N/A	-71.76%	-60.78%

Does the MarketBeat Community believe in COGT or ENLV?

Cogent Biosciences received 229 more outperform votes than Enlivex Therapeutics when rated by MarketBeat users. However, 79.10% of users gave Enlivex Therapeutics an outperform vote while only 70.68% of users gave Cogent Biosciences an outperform vote.

Company	Underperform	Outperform
Cogent Biosciences	Outperform Votes 282 70.68%	Underperform Votes 117 29.32%
Enlivex Therapeutics	Outperform Votes 53 79.10%	Underperform Votes 14 20.90%

Do institutionals & insiders have more ownership in COGT or ENLV?

1.0% of Enlivex Therapeutics shares are held by institutional investors. 5.9% of Cogent Biosciences shares are held by company insiders. Comparatively, 12.3% of Enlivex Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Which has stronger valuation and earnings, COGT or ENLV?

Cogent Biosciences is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$192.41M	-$2.48	-4.73
Enlivex Therapeutics	N/A	N/A	-$29.07M	-$1.18	-1.15

Does the media prefer COGT or ENLV?

In the previous week, Enlivex Therapeutics had 2 more articles in the media than Cogent Biosciences. MarketBeat recorded 3 mentions for Enlivex Therapeutics and 1 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 0.83 beat Enlivex Therapeutics' score of 0.33 indicating that Cogent Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cogent Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Enlivex Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do analysts prefer COGT or ENLV?

Cogent Biosciences currently has a consensus target price of $14.67, suggesting a potential upside of 25.14%. Enlivex Therapeutics has a consensus target price of $6.00, suggesting a potential upside of 341.18%. Given Enlivex Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Enlivex Therapeutics is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71
Enlivex Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.50

Which has more risk and volatility, COGT or ENLV?

Cogent Biosciences has a beta of 1.72, meaning that its stock price is 72% more volatile than the S&P 500. Comparatively, Enlivex Therapeutics has a beta of 1.11, meaning that its stock price is 11% more volatile than the S&P 500.

Summary

Enlivex Therapeutics beats Cogent Biosciences on 11 of the 16 factors compared between the two stocks.